S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
The New Energy Crisis No One Saw Coming (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
The Next Big Crisis Is Here (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
"We need batteries. Literally everywhere." (Ad)
Chevron Delights Shareholders with $75 Billion in Share Buybacks
Mergers and Acquisitions in 2023 Off To A Strong Start
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
The New Energy Crisis No One Saw Coming (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
The Next Big Crisis Is Here (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
"We need batteries. Literally everywhere." (Ad)
Chevron Delights Shareholders with $75 Billion in Share Buybacks
Mergers and Acquisitions in 2023 Off To A Strong Start
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
The New Energy Crisis No One Saw Coming (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
The Next Big Crisis Is Here (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
"We need batteries. Literally everywhere." (Ad)
Chevron Delights Shareholders with $75 Billion in Share Buybacks
Mergers and Acquisitions in 2023 Off To A Strong Start
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
The New Energy Crisis No One Saw Coming (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
The Next Big Crisis Is Here (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
"We need batteries. Literally everywhere." (Ad)
Chevron Delights Shareholders with $75 Billion in Share Buybacks
Mergers and Acquisitions in 2023 Off To A Strong Start
NASDAQ:CPRX

Catalyst Pharmaceuticals - CPRX Stock Forecast, Price & News

$15.99
-0.74 (-4.42%)
(As of 01/26/2023 12:00 AM ET)
Add
Compare
Today's Range
$15.87
$16.98
50-Day Range
$14.76
$21.05
52-Week Range
$5.24
$22.11
Volume
2.91 million shs
Average Volume
2.96 million shs
Market Capitalization
$1.66 billion
P/E Ratio
26.21
Dividend Yield
N/A
Price Target
$20.38

Catalyst Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
27.4% Upside
$20.38 Price Target
Short Interest
Healthy
10.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.99
Upright™ Environmental Score
News Sentiment
0.61mentions of Catalyst Pharmaceuticals in the last 14 days
Based on 19 Articles This Week
Insider Trading
Selling Shares
$14.87 M Sold Last Quarter
Proj. Earnings Growth
30.14%
From $0.73 to $0.95 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.97 out of 5 stars

Medical Sector

172nd out of 1,048 stocks

Pharmaceutical Preparations Industry

80th out of 513 stocks


CPRX stock logo

About Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Receive CPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPRX Stock News Headlines

Pliant Therapeutics Gaps 34% Higher: More Upside To Come? (CPRX)
Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment.
2 Biotechs Making Waves With A Single Product in their Pipeline (CPRX)
Catalyst Pharmaceuticals and Harmony Bioscience each have a single product in their respective pipelines, and both show incredible promise.
"We need batteries. Literally everywhere."
Pretty much every technological megatrend today requires batteries. That includes EVs... 5G... AI... charging stations... and smart energy storage systems. Find out why the U.S. just added graphite to a list of super-critical minerals, calling it "essential for America's National Defense."
Down 30% in a Day, Is Catalyst Pharmaceuticals Doomed?
"We need batteries. Literally everywhere."
Pretty much every technological megatrend today requires batteries. That includes EVs... 5G... AI... charging stations... and smart energy storage systems. Find out why the U.S. just added graphite to a list of super-critical minerals, calling it "essential for America's National Defense."
Catalyst Pharmaceuticals (NASDAQ:CPRX) Shares Gap Down to $20.80
3 Reasons Growth Investors Will Love Catalyst (CPRX)
Top Picks 2023- Catalyst Pharmaceutical CPRX
Top Picks 2023- Catalyst Pharmaceuticals CPRX
See More Headlines
Receive CPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPRX Company Calendar

Last Earnings
11/09/2022
Today
1/27/2023
Next Earnings (Estimated)
3/15/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CPRX
Employees
76
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$20.38
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$15.50
Forecasted Upside/Downside
+27.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$39.48 million
Pretax Margin
44.08%

Debt

Sales & Book Value

Annual Sales
$140.83 million
Cash Flow
$0.37 per share
Book Value
$2.01 per share

Miscellaneous

Free Float
89,397,000
Market Cap
$1.66 billion
Optionable
Optionable
Beta
1.19

Social Links


Key Executives

  • Mr. Patrick J. McEnanyMr. Patrick J. McEnany (Age 76)
    Co-Founder, Chairman, Pres & CEO
    Comp: $1.05M
  • Ms. Alicia  Grande C.M.A.Ms. Alicia Grande C.M.A. (Age 52)
    CPA, CMA, CPA, Chief Accounting Officer, VP, Treasurer & CFO
    Comp: $617.94k
  • Dr. Steven R. Miller Ph.D.Dr. Steven R. Miller Ph.D. (Age 61)
    COO & Chief Scientific Officer
    Comp: $745.71k
  • Dr. Gary  Ingenito M.D.Dr. Gary Ingenito M.D. (Age 67)
    Ph.D., Chief Medical & Regulatory Officer
    Comp: $706.86k
  • Dr. Preethi Sundaram Ph.D. (Age 47)
    Chief Strategy Officer
    Comp: $511.25k
  • Ms. Mary Coleman
    VP & Head of Investor Relations
  • Mr. Brian Elsbernd J.D. (Age 59)
    Chief Compliance Officer & Chief Legal Officer
  • Mr. Pete Curry Sr.
    VP of Sales
  • Mr. Jeffrey Del Carmen (Age 52)
    Chief Commercial Officer
  • Mr. Philip B. Schwartz (Age 68)
    Corp. Sec.













CPRX Stock - Frequently Asked Questions

Should I buy or sell Catalyst Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CPRX shares.
View CPRX analyst ratings
or view top-rated stocks.

What is Catalyst Pharmaceuticals' stock price forecast for 2023?

4 analysts have issued 1 year price objectives for Catalyst Pharmaceuticals' shares. Their CPRX share price forecasts range from $15.50 to $24.00. On average, they predict the company's stock price to reach $20.38 in the next year. This suggests a possible upside of 27.4% from the stock's current price.
View analysts price targets for CPRX
or view top-rated stocks among Wall Street analysts.

How have CPRX shares performed in 2023?

Catalyst Pharmaceuticals' stock was trading at $18.60 at the start of the year. Since then, CPRX stock has decreased by 14.0% and is now trading at $15.99.
View the best growth stocks for 2023 here
.

When is Catalyst Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 15th 2023.
View our CPRX earnings forecast
.

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) issued its earnings results on Wednesday, November, 9th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.01. The biopharmaceutical company earned $57.24 million during the quarter, compared to analysts' expectations of $53.80 million. Catalyst Pharmaceuticals had a trailing twelve-month return on equity of 28.53% and a net margin of 34.90%.

What guidance has Catalyst Pharmaceuticals issued on next quarter's earnings?

Catalyst Pharmaceuticals issued an update on its FY 2022 earnings guidance on Friday, December, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $205.00 million-$210.00 million, compared to the consensus revenue estimate of $205.03 million.

What other stocks do shareholders of Catalyst Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD).

What is Catalyst Pharmaceuticals' stock symbol?

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

Who are Catalyst Pharmaceuticals' major shareholders?

Catalyst Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.40%), Artemis Investment Management LLP (0.25%), Cyndeo Wealth Partners LLC (0.10%), SummerHaven Investment Management LLC (0.10%), Yousif Capital Management LLC (0.07%) and State of Alaska Department of Revenue (0.06%). Insiders that own company stock include Alicia Grande, Charles B O'keeffe, David S Tierney, Donald A Denkhaus, Gary Ingenito, Patrick J Mcenany, Philip H Coelho, Preethi Sundaram and Steve Miller.
View institutional ownership trends
.

How do I buy shares of Catalyst Pharmaceuticals?

Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catalyst Pharmaceuticals' stock price today?

One share of CPRX stock can currently be purchased for approximately $15.99.

How much money does Catalyst Pharmaceuticals make?

Catalyst Pharmaceuticals (NASDAQ:CPRX) has a market capitalization of $1.66 billion and generates $140.83 million in revenue each year. The biopharmaceutical company earns $39.48 million in net income (profit) each year or $0.61 on an earnings per share basis.

How can I contact Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The official website for the company is www.catalystpharma.com. The biopharmaceutical company can be reached via phone at (305) 420-3200, via email at bkorb@troutgroup.com, or via fax at 305-529-0933.

This page (NASDAQ:CPRX) was last updated on 1/27/2023 by MarketBeat.com Staff